Clinical Review

Judicious use of magnesium sulfate for eclampsia

OBG Manag. 2003 June;15(6):38-56

References

1. The Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: A randomised placebo-controlled trial. Lancet. 2002;359:1877-1890.

2. Coetzee EJ, Dommisse J, Anthony J. A randomized controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia. Br J Obstet Gynecol. 1998;105:300-303.

3. Witlin AG, Sibai BM. Magnesium sulfate therapy in preeclampsia and eclampsia. Obstet Gynecol. 1998;92:883-889.

4. Belfort MA, Anthony J, Saade GR, Allen JC. for the Nimodipine Study Group. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med. 2003;348:304-311.

5. Lucas MJ, Leveno KJ, Cunningham FG. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med. 1995;333:201-205.

6. The Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet. 1995;345:1455-1463

7. Belfort M, Moise KJ. Effect of magnesium sulfate on maternal brain blood flow in preeclampsia: A randomized, placebo-controlled study. Am J Obstet Gynecol. 1992;167:661-666.

8. Naidu S, Payne AJ, Moodley J, Hoffmann M, Gouws E. Randomized study assessing the effect of phenytoin and magnesium sulphate on maternal cerebral circulation in eclampsia using transcranial Doppler ultrasound. Br J Obstet Gynaecol. 1996;103:111-116.

9. Fawcett WJ, Haxby EJ, Male DA. Magnesium: Physiology and pharmacology. Br J Anaesthesia. 1999;83:302-320.

10. Yang Z-W, Gebrewold A, Nowakowski M, Altura BT, Altura BM. Mg²⁺ -induced endothelium-dependent relaxation of blood vessels and blood pressure lowering: role of NO. Am J Physiol. 2000;R628-R639.

11. Sipes SL, Weiner CP, Gellhaus TM, Goodspeed JD. Effects of magnesium sulfate infusion upon plasma prostaglandins in preeclampsia and preterm labor. Hypertens Pregnancy. 1994;13:293-302.

12. Richards A, Graham D, Bullock R. Clinicopathological study of neurological complications due to hypertensive disorders of pregnancy. J. Neurol Neurosurg Psych. 1988;51:416-421.

13. Pritchard JA. The use of magnesium sulfate in preeclampsia-eclampsia. J Reprod Med. 1979;23:107-114.

14. Lu JF, Nightingale CH. Magnesium sulfate in eclampsia and pre-eclampsia. Clin Pharmacokinet. 2000;38:305-314.

15. Sibai BM, Spinnato JA, Watson DL, Lewis JA, Anderson GD. Effect of magnesium sulfate on electroencephalographic findings in preeclampsia-eclampsia. Obstet Gynecol. 1984;64:261-266.

16. Sibai BM, Spinnato JA, Watson DL, Lewis JA, Anderson GD. Eclampsia. IV. Neurological findings and future outcome. Am J Obstet Gynecol. 1985;152:184-192.

17. Douglas KA, Redman CWG. Eclampsia in the United Kingdom. BMJ. 1994;309:1395-1400.

18. Sibai BM. Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol. 1990;163:1049-1055.

19. Sibai BM, Lipshitz J, Anderson GD, Dilts PV. Reassessment of intravenous MgSO⁴ therapy in preeclampsia-eclampsia. Obstet Gynecol. 1981;57:199.-

20. Katz VL, Farmer R, Kuller JA. Preeclampsia into eclampsia: Toward a new paradigm. Am J Obstet Gynecol. 2000;182:1389-1396.

21. Pritchard JA. The use of the magnesium ion in the management of eclamptogenic toxemias. Surg Gynecol Obstet. 1955;100:131-140.

22. Zuspan FP. Problems encountered in the treatment of pregnancy-induced hypertension. A point of view. Am J Obstet Gynecol. 1978;131:591-597.

23. Pritchard JA, Cunningham FG, Pritchard SA. The Parkland Memorial Hospital protocol for treatment of eclampsia: Evaluation of 245 cases. Am J Obstet Gynecol. 1984;148:951-960.

24. Usta IM, Sibai BM. Emergent management of puerperal eclampsia. Obstet Gynecol Clin N Am. 1995;22:315-333.

25. Ascarelli MH, Johnson V, May WL, Martin RW, Martin JN. Individually determined postpartum magnesium sulfate therapy with clinical parameters to safely and cost-effectively shorten treatment for pre-eclampsia. Am J Obstet Gynecol. 1998;179:952-956.

26. Isler CM, Barrilleaux PS, Rinehart BK, Magann EF, Martin JN, Jr. Postpartum seizure prophylaxis: Using maternal clinical parameters to guide therapy. Obstet Gynecol. 2003;101:66-69.

27. Atkinson MW, Guinn D, Owen J, Hauth JC. Does magnesium sulfate affect the length of labor induction in women with pregnancy-associated hypertension? Am J Obstet Gynecol. 1995;173:1219-1222.

28. Witlin AG, Friedman SA, Sibai BM. The effect of magnesium sulfate therapy on the duration of labor in women with mild preeclampsia at term: A randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 1997;177:623-627.

29. Riaz M, Porat R, Brodsky NL, Hurt J. The effects of maternal magnesium sulfate treatment on newborns: A prospective controlled study. Perinatology. 1998;18:449-454.

Serum magnesium levels can guide therapy in patients with signs of toxicity, renal insufficiency, or recurrent seizures, but offer no advantage over close clinical scrutiny in typical patients. Steady-state plasma magnesium levels are about the same in the fetus as in the mother to whom magnesium is administered.²¹ High fetal levels can impair fetal breathing movements, which could lower biophysical profile scores in the absence of significant fetal hypoxia.

Pulmonary function. Onset of a dry cough should raise suspicion of incipient pulmonary edema. Pulmonary auscultation detects rales that can accompany disease- or therapy-related pulmonary edema. Pulse oximetry, which provides continuous arterial oxygen saturation levels, can be very helpful in alerting the health-care team to both magnesium-induced respiratory depression and significant limitations in pulmonary gas exchange that accompany pulmonary edema.
Urine output. In the presence of oliguria (less than 100 mL in 4 hours), the rate of magnesium administration should be reduced by 50%.

The effects of magnesium toxicity can be rapidly reversed with 1 g IV calcium chloride or calcium gluconate. Seriously affected patients, however, may require dialysis to lower maternal magnesium concentrations, due to the long half-life of magnesium in plasma (approximately 4 hours in normal gravidas).

Also give IV calcium chloride or calcium gluconate for respiratory depression or other signs of cardiorespiratory toxicity. Immediate intubation with assisted ventilation is necessary in cases of cardiorespiratory failure. Fortunately, this phenomenon occurs very rarely with proper patient selection and rigorous surveillance.

TABLE 4

Monitoring guidelines for patients receiving magnesium

FUNCTION	WHEN TO MONITOR	SUSPECT MAGNESIUM TOXICITY AND COMPLICATIONS WHEN…
Patellar reflexes	Every 1–4 h*	Reflexes are absent
Respiratory rate	Every 1–4 h*	Rate is
Pulmonary auscultation	Every 12 h or with development of respiratory symptoms or signs	Rales are present
Pulse oximetry	Every 1–4 h*
Urine output	Every 1–4 h*
Serum magnesium levels	In presence of oliguria, persistent seizures, or signs of toxicity	>8 mEq/L
*Depending on clinical state

The authors report no affiliations or financial arrangements with any of the manufacturers of products mentioned in this article.